» Articles » PMID: 30542710

MiR‑144‑3p Regulates the Resistance of Lung Cancer to Cisplatin by Targeting Nrf2

Overview
Journal Oncol Rep
Specialty Oncology
Date 2018 Dec 14
PMID 30542710
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Chemotherapeutic drug resistance is correlated with treatment failure and poor prognosis among lung cancer patients. Numerous studies indicate the relevance of miRNAs in inducing certain drug resistance. In the course of the study, we unexpectedly found that miR‑144‑3p could regulate the cisplatin resistance of lung cancer cells via Nrf2. However, Nrf2 also could reverse activate the expression of miR‑144‑3p by binding to the ARE box in the miR‑144‑3p promoter. This may be a self‑protection mechanism of the body. In addition, we also found that in other cancer cell lines, such as HepG2, miR‑144‑3p also had the function of regulating cisplatin resistance. These findings may provide some theoretical reference for the clinical inhibition of cisplatin resistance.

Citing Articles

MicroRNAs in lung cancer: their role in tumor progression, biomarkers, diagnostic, prognostic, and therapeutic relevance.

Chatterjee M, Nag S, Gupta S, Mukherjee T, Shankar P, Parashar D Discov Oncol. 2025; 16(1):293.

PMID: 40067551 PMC: 11896959. DOI: 10.1007/s12672-025-02054-9.


FTO/m6A mediates miR-138-5p maturation and regulates gefitinib resistance of lung adenocarcinoma cells by miR-138-5p/LCN2 axis.

Ding D, Shang W, Shi K, Ying J, Wang L, Chen Z BMC Cancer. 2024; 24(1):1270.

PMID: 39394098 PMC: 11470737. DOI: 10.1186/s12885-024-13036-5.


Nrf2 in human cancers: biological significance and therapeutic potential.

Tian Y, Tang L, Wang X, Ji Y, Tu Y Am J Cancer Res. 2024; 14(8):3935-3961.

PMID: 39267682 PMC: 11387866. DOI: 10.62347/LZVO6743.


Identification of a prognostic gene signature in patients with cisplatin resistant squamous cell lung cancer.

Mu Y, Dong Y, Zheng M, Barr M, Roviello G, Hu Z J Thorac Dis. 2024; 16(7):4567-4583.

PMID: 39144297 PMC: 11320240. DOI: 10.21037/jtd-24-827.


The Cancer Antioxidant Regulation System in Therapeutic Resistance.

Gu X, Mu C, Zheng R, Zhang Z, Zhang Q, Liang T Antioxidants (Basel). 2024; 13(7).

PMID: 39061847 PMC: 11274344. DOI: 10.3390/antiox13070778.